TLDR: Via Scientific Raises $5M in Seed Funding
Via Scientific, a developer of a platform for discovering novel biological insights, has raised $5M in seed funding. The funding round was led by G20 Ventures and Innospark Ventures, with participation from other investors including Melissa J. Moore, Rob Hickey, and Janet Kosloff. Via Scientific plans to use the funds to accelerate its go-to-market activities, expand its technology and scientific teams, and extend its library of bioinformatic processes, pipelines, and AI models.
- Via Scientific raises $5M in seed funding
- Investors include G20 Ventures and Innospark Ventures
- The funds will be used to accelerate go-to-market activities, expand teams, and extend the library of bioinformatic processes and AI models
Summary
Via Scientific, a Boston-based company, has secured $5M in seed funding for its platform that enables pharmaceutical companies, bio-techs, and academic researchers to discover novel biological insights. The funding round was led by G20 Ventures and Innospark Ventures, with participation from investors including Melissa J. Moore, former CSO of Moderna, Rob Hickey, former EVP at DataRobot, and Janet Kosloff, founder, and former CEO of InCrowd, Inc. The company plans to use the funds to accelerate its go-to-market activities, expand its technology and scientific teams, and extend its library of bioinformatic processes, pipelines, and AI models.
Via Scientific, led by CEO Jim Crowley and CTO Alper Kucukural, has developed Via Foundry, a multi-omics platform that allows researchers to study life more comprehensively. The platform leverages AI to analyze large scale, complex, and dynamic biological data, enabling researchers to identify novel associations between biological entities, relevant biomarkers and pathways, and markers of disease and physiology.
